Inventor · disambiguated record
Jeffrey Browning
Also filed as: BROWNING JEFFREY · BROWNING JEFFREY L
43 granted patents·19 pending applications·1,030 citations·filing 1991–2019
98Inventor score
Top patents by PatentIndex Score
62 records- 0197US7083785B2Methods of treatment by administering an anti-BCMA antibodyBIOGEN IDEC INC·Filed 2002·Granted Aug 1, 2006·151 cites·18 claims
- 0297US7001598B2Anti-lymphotoxin-beta receptor antibodies as anti-tumor agentsBIOGEN IDEC INC·Filed 2001·Granted Feb 21, 2006·67 cites·132 claims
- 0395US7799902B2Receptor coupling agents and compositions thereofBIOGEN IDEC INC·Filed 2006·Granted Sep 21, 2010·29 cites·41 claims
- 0495US7566769B2Tumor necrosis factor related ligandBIOGEN IDEC INC·Filed 2006·Granted Jul 28, 2009·26 cites·27 claims
- 0594US7459537B2Anti-lymphotoxin-β receptor antibodies as anti-tumor agentsBIOGEN IDEC INC·Filed 2005·Granted Dec 2, 2008·11 cites·23 claims
- 0693US9650430B2Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)BIOGEN MA INC·Filed 2014·Granted May 16, 2017·8 cites·10 claims
- 0793US7208151B2Tweak receptor agonists as anti-angiogenic agentsBIOGEN IDEC INC·Filed 2001·Granted Apr 24, 2007·36 cites·13 claims
- 0893US6869605B2BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2001·Granted Mar 22, 2005·75 cites·14 claims
- 0993US5925351ASoluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseaseBIOGEN INC·Filed 1995·Granted Jul 20, 1999·78 cites·16 claims
- 1092US7030080B2Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereofUNIV CALIFORNIA·Filed 2001·Granted Apr 18, 2006·37 cites·5 claims
- 1191US7109298B2Tumor necrosis factor related ligandBIOGEN IDEC INC·Filed 2004·Granted Sep 19, 2006·25 cites·10 claims
- 1290US7731963B2TWEAK receptor agonists as anti-angiogenic agentsBIOGEN IDEC INC·Filed 2007·Granted Jun 8, 2010·11 cites·33 claims
- 1390US7695934B2Tumor necrosis factor related ligandBIOGEN IDEC INC·Filed 2006·Granted Apr 13, 2010·11 cites·23 claims
- 1490US6312691B1Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agentsFiled 1996·Granted Nov 6, 2001·52 cites·5 claims
- 1589US7087725B2Antibodies specifically reactive with a tumor necrosis factor related ligandBIOGEN IDEC INC·Filed 2004·Granted Aug 8, 2006·23 cites·19 claims
- 1688US7060667B1Treatment of follicular lymphomas using inhibitors of the LT pathwayUNIV NEW YORK·Filed 2000·Granted Jun 13, 2006·37 cites·25 claims
- 1788US6403087B1Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological diseaseBIOGEN INC·Filed 1996·Granted Jun 11, 2002·52 cites·14 claims
- 1887US7846438B2Methods of promoting neurite outgrowth with soluble TAJ polypeptidesBIOGEN IDEC INC·Filed 2005·Granted Dec 7, 2010·8 cites·16 claims
- 1986US6669941B1Soluble lymphotoxin-β receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune diseaseBIOGEN INC·Filed 1999·Granted Dec 30, 2003·42 cites·14 claims
- 2084US10494416B2Methods of modulating immune responses using BCMA polypeptideBIOGEN MA INC·Filed 2017·Granted Dec 3, 2019·1 cites·7 claims
- 2183US7947271B2Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agentsBIOGEN IDEC INC·Filed 2010·Granted May 24, 2011·6 cites·32 claims
- 2283US7309492B2Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of systemic lupus erythematosusBIOGEN IDEC INC·Filed 2001·Granted Dec 18, 2007·13 cites·7 claims
- 2383US5795964ALymphotoxin-beta and lymphotoxin-beta complexesBIOGEN INC·Filed 1995·Granted Aug 18, 1998·37 cites·11 claims
- 2483US5670149ALymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereofBIOGEN INC·Filed 1995·Granted Sep 23, 1997·38 cites·3 claims
- 2581US8338376B2Compositions comprising variant LT-B-R-IG fusion proteinsBECKMAN EVAN·Filed 2009·Granted Dec 25, 2012·4 cites·77 claims
- 2681US7744891B2Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseasesBIOGEN IDEC INC·Filed 2007·Granted Jun 29, 2010·3 cites·35 claims
- 2781US7618933B2Treatment of follicular lymphomas using inhibitors of the LT pathwayUNIV NEW YORK·Filed 2006·Granted Nov 17, 2009·2 cites·20 claims
- 2881US7427403B2Methods for inhibiting lymphotoxin β receptor signallingBIOGEN IDEC INC·Filed 2002·Granted Sep 23, 2008·9 cites·74 claims
- 2980US7951371B2Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signalingBIOGEN IDEC INC·Filed 2007·Granted May 31, 2011·2 cites·12 claims
- 3079US8828669B2Methods of screening for a compound that inhibits the interaction between BAFF and BCMABROWNING JEFFREY·Filed 2012·Granted Sep 9, 2014·1 cites·2 claims
- 3178US8283138B2Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteinsBROWNING JEFFREY L·Filed 2009·Granted Oct 9, 2012·3 cites·26 claims
- 3276US7585946B2Active lymphotoxin-β receptor immunoglobulin chimeric protein compositionsBIOGEN IDEC INC·Filed 2001·Granted Sep 8, 2009·8 cites·18 claims
- 3376US7129061B1Tumor necrosis factor related ligandFACULTY OF MEDICINE OF THE UNI·Filed 1999·Granted Oct 31, 2006·24 cites·45 claims
- 3476US5661004ALymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereofBIOGEN INC·Filed 1995·Granted Aug 26, 1997·42 cites·5 claims
- 3576US2020095305A1Methods of modulating immune responses using bcma polypeptideBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 3675US7452530B2Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathwayBIOGEN IDEC INC·Filed 2004·Granted Nov 18, 2008·9 cites·28 claims
- 3773US8709759B2Method for increasing expression of active tumor necrosis factor receptor family member-Ig fusion proteinsBROWNING JEFFREY·Filed 2012·Granted Apr 29, 2014·2 cites·9 claims
- 3872US8142779B2Treatment of follicular lymphomas using inhibitors of the LT pathwayBROWNING JEFFREY·Filed 2009·Granted Mar 27, 2012·0 cites·19 claims
- 3972US7255854B1Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseasesBIOGEN INC·Filed 1999·Granted Aug 14, 2007·21 cites·35 claims
- 4069US5484711ADNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VIBIOGEN INC·Filed 1993·Granted Jan 16, 1996·18 cites·8 claims
- 4168US2009123421A1Anti-lymphotoxin-beta receptor antibodies as anti-tumor agentsBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 4267US2010260761A1Antibodies specifically reactive with a tumor necrosis factor related ligandBIOGEN INC·Filed 2006·Application pending·0 cites
- 4364US2010233179A1BAFF, inhibitors thereof and their use in the modulation of B-cell responseBROWNING JEFFREY·Filed 2009·Application pending·0 cites
- 4458US8455445B2Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disordersBROWNING JEFFREY L·Filed 2011·Granted Jun 4, 2013·0 cites·16 claims
- 4558US8067375B2Treatment of demyelinating disorders with soluble lymphotoxin-β-receptorBROWNING JEFFREY L·Filed 2007·Granted Nov 29, 2011·0 cites·32 claims
- 4658US2005100548A1BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2004·Application pending·0 cites
- 4756US2009087403A1Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathwayBROWNING JEFFREY·Filed 2008·Application pending·0 cites
- 4856US2006079457A1BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 4955US2005169924A1BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 5054US8287874B2Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseasesBROWNING JEFFREY L·Filed 2010·Granted Oct 16, 2012·0 cites·29 claims
Showing the top 50 of 62 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →